The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Chugai Pharma; Miyarisan Pharmaceutical
OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer.
 
Kiyotaka Yoh
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; DaiichiSankyo; Janssen; Merck KGaA; MSD; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer; BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst)
 
Yoshiro Nakahara
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - JSPS KAKENHI; The Japan Lung Cancer Society
 
Reiko Isomura
No Relationships to Disclose
 
Toshihiro Misumi
No Relationships to Disclose
 
Motohiro Tamiya
Honoraria - Amgen; Asahi Kasei; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin International; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Pfizer
Research Funding - Boehringer Ingelheim; MSD; Ono Pharmaceutical
 
Naoki Furuya
No Relationships to Disclose
 
Akira Ono
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Janssen Research & Development (Inst)
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD Oncology; Taiho Pharmaceutical
 
Kenichi Koyama
No Relationships to Disclose
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca
Research Funding - AstraZeneca; Chugai Pharma (Inst)
 
Kageaki Watanabe
Consulting or Advisory Role - GUARDANT HEALTH JAPAN CORP
Speakers' Bureau - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chugai Pharma; Merck; MSD K.K.; Novartis; Ono Pharmaceutical; RIKEN GENESIS CO.,LTD.; Sysmex
 
Takaaki Tokito
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Chugai Pharma; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical
 
Nobuhiko Seki
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD Oncology; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly Japan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim; Lilly; Nippon Kayaku
 
Hisao Imai
No Relationships to Disclose
 
Takehito Shukuya
Honoraria - AMGEN; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Nippon kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Chugai Pharma; MSD; Novartis
 
Yuji Shibata
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Blueprint Medicines (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst)
 
Shinobu Hosokawa
Speakers' Bureau - AstraZeneca Japan; Bristol Myers Squibb K.K.; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Toshiyuki Kozuki
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroaki Okamoto
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)